Company profile
CytomX Therapeutics, Inc.
NASDAQ: CTMX · Healthcare · Biotechnology
#379 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
63CFH 60DQ 76GM 45SS 62
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$18.3M
Rev growth YoY (TTM)
-87.0%
Net income (FY)
-$17.4M
Employees
69
as of 2026-08-11
Market cap
$748.9M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$76.2M$76.2M2025
Net income-$17.4M-$17.4M2025
Operating income-$22.4M-$22.4M2025
Total assets$151.6M$151.6M2025
Liabilities$52.6M$52.6M2025
Equity$99.0M$99.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CytomX Therapeutics, Inc.’s revenue?
CytomX Therapeutics, Inc. booked $76.2M in FY2025 revenue, contracting 45% year over year — slower than 80% of Healthcare companies we track, at a -22.8% net margin.
Peers · Healthcare
Vitalhub Corp.77B+Sight Sciences, Inc.53DCannara Biotech Inc.76B+Interpharm Holdings, Inc.——Lifecore Biomedical, Inc.66BAbCellera Biologics Inc.54DNeighbors
San Mateo →Key facts
CEOSean A. McCarthy
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: CTMX
Employees69
IPO date2015-10-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.